K-numberK243681
Device nameNeuro Insight V1.0
ApplicantOlea Medical S.A.S.
Product codeLLZ
Device classClass II
Decision dateJul 23, 2025
DecisionSubstantially Equivalent
Regulation892.2050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Neuro Insight V1.0 is an image processing software solution composed of NeuroPro (an image processing application that computes maps and metrics from neurological MRI images) and Neuro Synchronizer (an optional interface for viewing, manipulating, and comparing medical images). It is intended to assist appropriately trained medical professionals in analyzing neurological MRI studies and does not alter original images or serve as a standalone diagnostic tool.

Technological characteristics

Both Neuro Insight V1.0 and predicate Olea Sphere V3.0 process FLAIR, T1, T2, T1g, diffusion, and DSC perfusion series and produce identical parametric map outputs (CBV, CBF, MTT, TTP, Tmax/Delay, CBV_corr, K2, tMIP). Key differences: Neuro Insight uses 3D rigid motion correction (already cleared in K223502) and a 3D deep learning brain extraction tool (achieving DICE coefficient of 0.97), while Olea Sphere uses 2D rigid correction and histogram-based thresholds. Neuro Insight also uses 3D rigid 6-dof co-registration versus Olea Sphere's DICOM tag-based alignment.

Test standards cited

Not stated in this summary.

Substantial equivalence argument

Neuro Insight V1.0 represents a subset of Olea Sphere V3.0, providing MR-only processing versus Olea Sphere's MR and CT capabilities. The intended use, indications, and principles of operation are substantially equivalent—both are analysis tools for clinicians reviewing neurological MRI, neither diagnoses independently, and both require clinical judgment. The minor technological differences (motion correction, brain extraction, co-registration methods) do not raise new safety or effectiveness questions because the 3D motion correction was previously cleared (K223502), the deep learning brain extraction achieved excellent validation metrics (DICE 0.97), and the user confirmation feature for adjusted parameters (arterial input function) is already present in cleared reference device Olea S.I.A Neurovascular V1.0 (K223532). Quantitative and qualitative comparisons by three board-certified neuroradiologists using 30 anonymized cases confirmed substantial equivalence of parametric map outputs, and qualitative assessment of 60 cases confirmed acceptable co-registration quality.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →